Management Team

Alexander L. Weis, PhD
Chairman, CEO & President

Co-founder of ILEX Oncology.
Founder of Lipitek, worked with Vector Therapeutics, Sterling Winthrop, Weizmann Institute, CTRC.
Fellow of the Royal Society of Chemistry.
South Texas Entrepreneur of the Year in 1996.
20+ years in bio-pharmaceutical industry; over 60 publications and 28 patents.
[ top of page ]

Clinical Advisory Board

Eric Rowinsky, MD (Chairman of the SAB)

Senior VP and Chief Medical Officer at ImClone Systems, Inc.
Key role in development of: Taxol® and Hycamtin®.
[ top of page ]

Esteban Cvitkovic, MD

Key role in development of: Eloxatin™, Taxotere® and Camptosar®
[ top of page ]

Ronald P. McCaffrey, MD

Harvard Medical School
Massachusetts General Hospital
[ top of page ]

Pedro Santabarbara, MD, PhD

VP Strategic Development and Medical Affairs at PHARMA MAR S.A.
Key role in development of: Taxol®;, Taxotere®, Campath®; and Tarceva®.
[ top of page ]

Allan M. Green, MD, PhD, JD

Expert in FDA regulatory matters and business strategy
Advisor to pharmaceutical industry
[ top of page ]